2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100325
    NHE3-IN-1 632355-68-1 98.05%
    NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1.
    NHE3-IN-1
  • HY-100328
    CB2R-IN-1 1257555-79-5 98%
    CB2R-IN-1 is a potent cannabinoid CB2 receptor inverse agonist with a Ki of 0.9 nM.
    CB2R-IN-1
  • HY-100356
    Aptiganel 137159-92-3 98%
    Aptiganel (CNS 1102 (free base)), peptide, is a noncompetitive NMDA antagonist with cerebroprotective effects. Aptiganel can be used for the research of stroke.
    Aptiganel
  • HY-10035A
    (R)-TTA-P2 99.95%
    (R)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease.
    (R)-TTA-P2
  • HY-100377
    Lvguidingan 82351-05-1 99.48%
    Lvguidingan is a potent anticonvulsant agent. Lvguidingan also has sedative-hypnotic, tranquilizing, and muscle-relaxing actions. Lvguidingan can be used as antiepileptic agent.
    Lvguidingan
  • HY-100481
    RP 72540 139088-45-2 98%
    RP 72540 is a selective CCK-B receptor antagonist, with IC50 values of 2.4, 1.2, and 3.8 nM for CCK-B receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits CCK-8-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors.
    RP 72540
  • HY-10049A
    CP 122721 hydrochloride 145877-52-7 98%
    CP 122721 hydrochloride is a potent, non-peptide and selective nonpeptide neurokinin NK1 antagonist, with a pIC50 of 9.8 for human NK1 receptor expressed in IM-9 cells. CP 122721 hydrochloride exhibits anxiolytic and antidepressant-like effects.
    CP 122721 hydrochloride
  • HY-10052R
    Aprepitant (Standard) 170729-80-3
    Aprepitant (Standard) is the analytical standard of Aprepitant. This product is intended for research and analytical applications. Aprepitant (MK-0869) is a selective and high-affinity neurokinin 1 receptor antagonist with a Kd of 86 pM.
    Aprepitant (Standard)
  • HY-10053S
    Maropitant-d3 2124295-52-7 98%
    Maropitant-d3 is the deuterium labeled Maropitant. Maropitant is a selective and orally active neurokinin (NK1) receptor antagonist. Maropitant acts by blocking the binding of substance P within the emetic center and the chemoreceptor trigger zone (CRTZ). Maropitant is highly effective in preventing vomiting.
    Maropitant-d3
  • HY-100634
    4-Hydroxypropranolol hydrochloride 14133-90-5 98%
    4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol. 4-Hydroxypropranolol hydrochlorid is of comparable potency to Propranolol. 4-Hydroxypropranolol hydrochlorid inhibits β1- and β2-adrenergic receptors with pA2 values of 8.24 and 8.26, respectively. 4-Hydroxypropranolol hydrochlorid has intrinsic sympathomimetic activity, membrane stabilizing activity and potent antioxidant properties.
    4-Hydroxypropranolol hydrochloride
  • HY-100642
    3-O-Methyltolcapone 134612-80-9 99.95%
    3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone. Tolcapone is an orally active, reversible, selective and potent COMT inhibitor. Tolcapone crosses the blood-brain barrier, and can be used for treatment of Parkinson's disease.
    3-O-Methyltolcapone
  • HY-100651
    Desmethylnortriptyline 4444-42-2 99.95%
    Desmethylnortriptyline is a metabolite of Nortriptyline (HY-118620). Nortriptyline is a tricyclic antidepressant and the main active metabolite of Amitriptyline (HY-B0527) , and is used to relieve the symptoms of depression.
    Desmethylnortriptyline
  • HY-100670
    Olinone 1770789-37-1 98%
    Olinone is a selective BRD4 BrD1 inhibitor. Olinone accelerates the progression of mouse primary oligodendrocyte progenitors toward differentiation.
    Olinone
  • HY-100723
    THK-523 1573029-17-0 98%
    THK-523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo. 18F-THK523 is a potent tau imaging radiotracer. 18F-THK523 is a potent in vivo tau imaging ligand for Alzheimer's disease.
    THK-523
  • HY-100778
    SMM-189 1054451-07-8 98%
    SMM-189 is  a potent and selective cannabinoid receptor 2 (CB2) inverse agonist. SMM-189 plays an important role in neurodegenerative disorders and traumatic brain injury research.
    SMM-189
  • HY-100781
    D-AP4 78739-01-2 98%
    D-AP4 (D-APB; D-2-Amino-4-phosphonobutyric acid), a phosphono analogue of glutamate, is an NMDA broad spectrum excitatory amino acid receptor antagonist. D-AP4 also is an agonist for a quisqualate-sensitized AP6 site in hippocampus. D-AP4 inhibits AMPA receptor-stimulated 57Co2+ influx in cultured cerebellar granule cells (IC50 ≥ 100 μM).
    D-AP4
  • HY-100782
    DL-AP7 85797-13-3 98%
    DL-AP7 is a competitive NMDA antagonist and an anticonvulsant. DL-AP7 blocks the NMDA-induced convulsions and impairs learning performance in a passive avoidance task in mice.
    DL-AP7
  • HY-100787
    L-Cysteine S-sulfate sodium 7381-67-1 98%
    L-Cysteine S-sulfate sodium is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations.
    L-Cysteine S-sulfate sodium
  • HY-100797
    (RS)-CPP 100828-16-8 ≥99.0%
    (RS)-CPP ((±)-CPP) is a potent and selective NMDA antagonist. (RS)-CPP inhibits central neuron responses, and has anticonvulsant activity.
    (RS)-CPP
  • HY-100802
    Homoquinolinic acid 490-75-5 98%
    Homoquinolinic acid is a non endogenous agonist of NMDAR2 receptor.
    Homoquinolinic acid
Cat. No. Product Name / Synonyms Application Reactivity